Genzyme Hit With $50M Judgment In Fabry Treatment IP Fight

Law360, New York (July 18, 2012, 9:14 PM EDT) -- A Delaware jury found Tuesday that Genzyme Corp. had induced infringement of a Shelbyzyme LLC patent covering a method of treating a rare genetic disease, awarding Shelbyzyme $50 million in damages.

Although the jury found that Genzyme had not literally infringed three claims for U.S. Patent Number 7,011,831, which covers a method for treating Fabry disease by administering an enzyme, the jury found that Genzyme had induced and contributed to the patent's infringement.

The jury also rejected Genzyme's defense that '831 patent was invalid for lack...
To view the full article, register now.